UNKNOWN IMPLANTABLE NEUROSTIMULATOR NEU_INS_STIMULATOR

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,l report with the FDA on 2019-01-17 for UNKNOWN IMPLANTABLE NEUROSTIMULATOR NEU_INS_STIMULATOR manufactured by Medtronic Neuromodulation.

Event Text Entries

[133523567] This value reflects the gender of the majority of the patients reported in the article as specific patients could not be identified. Please note that this date is based off of the date of publication of the article as the event dates were not provided in the published literature. Other relevant device(s) are: product id: 3389, serial/lot #: unknown, product id: 3389, serial/lot #: unknown, product id: 3389, serial/lot #: unknown. Herrman, h. , egge, a. , konglund, ae. , ramm-pettersen, j. , dietrichs, e. , tauboll, e. Anterior thalamic deep brain stimulation in refractory epilepsy: a randomized, double-blinded study. Acta neurol scand. 2018. Doi: 10. 1111/ane. 13047 if information is provided in the future, a supplemental report will be issued.
Patient Sequence No: 1, Text Type: N, H10


[133523568] Summary: objectives- the safety and effect on seizure frequency of anterior thalamic nucleus deep brain stimulation (ant-dbs) were studied in this prospective, randomized, double-blinded study. Patients were followed for 12 months. The first 6 months were blinded with regard to active stimulation or not. After 6 months, all patients received active stimulation. Material and methods- bilateral ant electrodes were implanted into 18 patients suffering from focal, pharmacoresistant epilepsy. Antiepileptic treatment was kept unchanged from three months prior to operation. The liverpool seizure severity scale (lsss) was used to measure the burden of epilepsy. Results- there was no significant difference between the 2 groups at the end of the blinded period at 6 months. However, when considering all patients and comparing 6 months of stimulation with baseline, there was a significant, 22% reduction in the frequency of all seizures (p=0. 009). Four patients had = 50% reduction in total seizure frequency and 5 patients = 50% reduction in focal seizures after 6 months of stimulation. No increased effect over time was shown. Lsss at 6 months compared to baseline showed no significant difference between the 2 groups, but a small, significant reduction in lsss was found when all patients had received stimulation for 6 months. Conclusions- our study supports results from earlier studies concerning dbs as a safe treatment option, with effects even in patients with severe, refractory epilepsy. However, our results are not as encouraging as those reported from many other, mainly unblinded, and open studies. Reported events: 1 patient with bilateral ant-dbs for epilepsy in the initial active stimulation group reported being aware that the stimulation was turned on because they felt a tingling sensation at the site of the electrode. All patients were reportedly implanted with 3389 model leads. It was not possible to ascertain any other specific device information from the article or to match the reported event with any previously reported event.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3007566237-2019-00174
MDR Report Key8257674
Report SourceFOREIGN,HEALTH PROFESSIONAL,L
Date Received2019-01-17
Date of Report2019-01-17
Date of Event2018-10-25
Date Mfgr Received2019-01-04
Date Added to Maude2019-01-17
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactLISA WOODWARD CLARK
Manufacturer Street7000 CENTRAL AVENUE NE RCW215
Manufacturer CityMINNEAPOLIS MN 55432
Manufacturer CountryUS
Manufacturer Postal55432
Manufacturer Phone7635263920
Manufacturer G1MEDTRONIC NEUROMODULATION
Manufacturer Street800 53RD AVE NE
Manufacturer CityMINNEAPOLIS MN 554211200
Manufacturer CountryUS
Manufacturer Postal Code554211200
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameUNKNOWN IMPLANTABLE NEUROSTIMULATOR
Product CodeMBX
Date Received2019-01-17
Model NumberNEU_INS_STIMULATOR
Catalog NumberNEU_INS_STIMULATOR
Lot NumberUNKNOWN
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by Mfgr*
Device Sequence No1
Device Event Key0
ManufacturerMEDTRONIC NEUROMODULATION
Manufacturer Address800 53RD AVE NE MINNEAPOLIS MN 554211200 US 554211200


Patients

Patient NumberTreatmentOutcomeDate
10 2019-01-17

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.